Synthetic genistein derivatives as modulators of glycosaminoglycan storage

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Kloska, Anna ^a   Narajczyk, Magdalena ^a   Jakóbkiewicz Banecka, Joanna ^a   Grynkiewicz, Grzegorz ^b   Szeja, Wiesław ^c   Gabig Cimińska, Magdalena ^a   Wegrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^c SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Mucopolysaccharidoses; Substrate reduction therapy; Synthetic derivatives of genistein

Indexed keywords

2 [3 [4 [7 (BENZYLOXY) 5 HYDROXY 4 OXO 4H CHROMEN 3 YL]PHENOXYMETHYL]5 (1 CYANO 1 METHYLETHYL)PHENYL] 2 METHYLPROPANENITRILE; 2 [[5 HYDROXY 3 (4 HYDROXYPHENYL) 4 OXO 4H CHROMEN 7 YL]OXY]ACETIC ACID; 4 (5,7 DIHYDROXY 4 OXO 4H CHROMEN 3 YL)PHENYL 2 AMINOBENZOATE; 4 [5 HYDROXY 4 OXO 7 (PROP 2 EN 1 YLOXY) 4H CHROMEN 3 YL]PHENYL 2 (ACETYLOXY)BENZOATE; 4 [5,7 BIS(ACETYLOXY) 4 OXO 4H CHROMEN 3 YL]PHENYL ACETATE; 4 [7 (BENZYLOXY) 5 HYDROXY 4 OXO 4H CHROMEN 3 YL]PHENYL 1 SODIUM PENTANEDIOATE; 4 [7 (BENZYLOXY) 5 HYDROXY 4 OXO 4H CHROMEN 3 YL]PHENYL ACETATE; 5 [4 [7 (BENZYLOXY) 5 HYDROXY 4 OXO 4H CHROMEN 3 YL]PHENOXY] 5 OXOPENTANOIC ACID; 5 HYDROXY 3 (4 HYDROXYPHENYL) 4 OXO 4H CHROMEN 7 YL HEPTADECANOATE; 5 HYDROXY 3 (4 HYDROXYPHENYL) 7 (PROP 2 EN 1 YLOXY) 4H CHROMEN 4 ONE; 5 HYDROXY 3 (4 HYDROXYPHENYL) 7 [(4 METHOXYPHENYL)METHOXY] 4H CHROMEN 4 ONE; 5 HYDROXY 3 (4 HYDROXYPHENYL) 7 O (EPOXYMETHYL) 4H CHROMEN 4 ONE; 5 HYDROXY 7 (2 HYDROXETHOXY) 3 (4 HYDROXYPHENYL) 4H CHROMEN 4 ONE; 5,7 BIS(PROP 2 EN 1 YLOXY) 3 [4 (PROP 2 EN 1 YLOXY)PHENYL] 4H CHROMEN 4 ONE; 5,7 DIHYDROXY 3 [4 (PROPAN 2 YLOXY)PHENYL] 4H CHROMEN 4 ONE; 7 (BENZYLOXY) 5 (PROPAN 2 LOXY) 3 [4 (PROPAN 2 YLOXY)PHENYL] 4H CHROMEN 4 ONE; 7 (BENZYLOXY) 5 HYDROXY 3 [4 (PROP 2 EN 1 YLOXY)PHENYL] 4H CHROMEN 4 ONE; 7 (BENZYLOXY) 5 HYDROXY 3[4 (PROPAN 2 LOXY)PHENYL] 4H CHROMEN 4 ONE; 7 O [(2,3,4,6 TETRA O ACETYL BETA DEXTRO GALACTOPYRANOSYL) 1,4 (6 O ACETYL HEX 2 ENE ALPHA DEXTRO ERYTHROPYRANOSYL)] 5 HYDROXY 3 (HYDROXYPHENYL) 4H CHROMEN 4 ONE; [5 HYDROXY 3 (4 HYDROXYPHENYL) 4 OXO 4H CHROMEN 7 YL]PROP 2 EN 1 YL CARBONATE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ETHYL 2[[5 HYDROXY 3 (4 HYDROXYPHENYL) 4 OXO 4H CHROMEN 7 YL]OXY]ACETATE; GENISTEIN; GLYCOSAMINOGLYCAN; ISOFLAVONE; TERT BUTYL 2 [4 (5,7 DIHYDROXY 4 OXO 4H CHROMEN 3 YL)PHENOXY]ACETATE; TERT BUTYL 2 [[3 [4 [2 (TERT BUTOXY) 2 OXOETHOXY]PHENYL] 5 HYDROXY 4 OXO 4H CHROMEN 7 YL]OXY]ACETATE; TERT BUTYL 2[[5 HYDROXY 3 (4 HYDROXYPHENYL) 4 OXO 4H CHROMEN 7 YL]OXY]ACETATE; TETRABUTYLAMMONIUM 5 [[5 HYDROXY 3 (4 HYDROXYPHENYL) 4 OXO 4H CHROMEN 7 YL]OXY] 5 OXOPENTANOATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CARBOHYDRATE SYNTHESIS; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FIBROBLAST; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; PHYSICAL CHEMISTRY; PROTEIN PHOSPHORYLATION; SANFILIPPO SYNDROME;

BLOOD-BRAIN BARRIER; CELL LINE; FIBROBLASTS; GENISTEIN; GLYCOSAMINOGLYCANS; HUMANS; MICROSCOPY, ELECTRON;

EID: 84866174239     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-153     Document Type: Article

References (31)

1. Beck M. Mucopolysaccharidoses: clinical features and management. Genetic Metabolic Disorders: Management, Costs and Sociomedical Aspects 2007, 13-18. Deutscher Arzte-Verlag, Cologne, Dahl S, Wendel U, Strohmeyer G.
2. Neufeld EF, Muenzer J. The mucopolysaccharidoses. The metabolic and molecular bases of inherited disease 2001, 3421-3452. McGraw-Hill Co, New York, Scriver CR, Beaudet AL, Sly WS, Valle D.
3. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010, 62:33-40.
4. de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, Mengel E, Offringa M, O'Meara A, Parini R, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 2011, 6:55. 10.1186/1750-1172-6-55, 3170181, 21831279.
5. Wraith JE. Enzyme replacement therapy for the management of the mucopolysaccharidoses. Int J Clin Pharmacol Ther 2009, 47(Suppl 1):63-65.
6. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 2007, 121:1-22. 10.1007/s00439-006-0280-4, 17089160.
7. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006, 14:846-852. 10.1038/sj.ejhg.5201623, 16670689.
8. Pisano MM, Greene RM. Epidermal growth factor potentiates the induction of ornithine decarboxylase activity by prostaglandins in embryonic palate mesenchymal cells: effects on cell proliferation and glycosaminoglycan synthesis. Dev Biol 1987, 122:419-431. 10.1016/0012-1606(87)90306-X, 3109985.
9. Tirone E, D'Alessandris C, Hascall VC, Siracusa G, Salustri A. Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta1). J Biol Chem 1997, 272:4787-4794. 10.1074/jbc.272.8.4787, 9030534.
10. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262:5592-5595.
11. Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 2009, 16:26. 10.1186/1423-0127-16-26, 2653532, 19272193.
12. Wegrzyn G, Jakobkiewicz-Banecka J, Gabig-Ciminska M, Piotrowska E, Narajczyk M, Kloska A, Malinowska M, Dziedzic D, Golebiewska I, Moskot M, Wegrzyn A. Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem Soc Trans 2010, 38:695-701. 10.1042/BST0380695, 20298245.
13. Jakobkiewicz-Banecka J, Piotrowska E, Gabig-Ciminska M, Borysiewicz E, Slominska-Wojewodzka M, Narajczyk M, Wegrzyn A, Wegrzyn G. Substrate reduction therapies for mucopolysaccharidoses. Curr Pharm Biotechnol 2011, 12:1860-1865. 10.2174/138920111798376932, 21902626.
14. Wegrzyn A. Gene expression-targeted isoflavone therapy. IUBMB Life 2012, 64:307-315. 10.1002/iub.1007, 22362546.
15. Tsai TH. Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 2005, 1073:317-322. 10.1016/j.chroma.2004.10.048, 15909536.
16. Malinowska M, Wilkinson FL, Bennett W, Langford-Smith KJ, O'Leary HA, Jakobkiewicz-Banecka J, Wynn R, Wraith JE, Wegrzyn G, Bigger BW. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 2009, 98:235-242. 10.1016/j.ymgme.2009.06.013, 19632871.
17. Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, Vanier MT, Grynkiewicz G, Wynn RF, Wraith JE, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010, 5:e14192. 10.1371/journal.pone.0014192, 2995736, 21152017.
18. Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, Liberek A, Maryniak A, Malinowska M, Czartoryska B, Puk E, Kloska A, Liberek T, et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 2008, 63:166-179.
19. Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, Tylki-Szymanska A, Puk E, Liberek A, Wegrzyn A, Czartoryska B, Slominska-Wojewodzka M, Wegrzyn G. Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011, 17:CR196-CR202.
20. Delgadillo V, O'Callaghan Mdel M, Artuch R, Montero R, Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011, 34:1039-1044. 10.1007/s10545-011-9342-4, 21556833.
21. Malinova V, Wegrzyn G, Narajczyk M. The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy (GET IT) for Sanfilippo disease patients. JIMD Rep 2012, 5:21-25.
22. de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, Wagemans T, van der Wal WM, Wijburg FA. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012, 71:110-120. 10.1002/ana.22643, 22275257.
23. Arfi A, Richard M, Gandolphe C, Scherman D. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 2010, 33:61-67. 10.1007/s10545-009-9029-2, 20084460.
24. Kloska A, Jakobkiewicz-Banecka J, Narajczyk M, Banecka-Majkutewicz Z, Wegrzyn G. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab Brain Dis 2011, 26:1-8. 10.1007/s11011-011-9233-2, 3070076, 21305347.
25. Grynkiewicz G. Synthetic genistein as a prospective active ingredient for nutrition and medicine. Pol J Food Nutr Sci 2002, 52(Suppl 2):99-105.
26. Grynkiewicz G, Zegrocka-Stendel O, Pucko W, Ramza J, Kościelecka A, Kołodziejski W, Woźniak K. X-ray and 13 C CP MAS investigations of structure of two genistein derivatives. J Mol Struct 2004, 694:121-129.
27. Rusin A, Krawczyk Z, Grynkiewicz G, Gogler A, Zawisza-Puchalka J, Szeja W. Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim Pol 2010, 57:23-34.
28. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999, 88:815-821. 10.1021/js980402t, 10430548.
29. Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 2007, 48:383-388. 10.1007/BF03195237, 17998597.
30. Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 2006, 60:309-314. 10.1203/01.pdr.0000233037.00707.da, 16857766.
31. Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 2007, 92:115-121. 10.1016/j.ymgme.2007.06.016, 17681480.